As of November 14, 2026, Mereo BioPharma Group plc has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on March 27, 2026 (Form 8-K, March 27, 2026).
29 companies changed executives this week, 1 had other signals.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| ONITY GROUP INC. | announced the departure of its Chief Investment Officer | |
| Adicet Bio, Inc. | announced the departure of its Director | |
| MAMMOTH ENERGY SERVICES, INC. | announced the departure of its Chief Operating Officer | |
| CERENOME, INC. | named a new Director | |
| Cohen & Co Inc. | named a new Chief Executive Officer |
Sell to companies like Mereo BioPharma Group plc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Mereo BioPharma Group plc reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-03-27. Every row below is cited to the filing it comes from, and this page adds each new change as Mereo BioPharma Group plc files it.
Also on the record for Mereo BioPharma Group plc
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 28, 2026 | Stake report, Schedule 13G/A, by BANK OF AMERICA CORP /DE/ | 3.4% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by EcoR1 Capital, LLC | 0.6% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by EcoR1 Capital, LLC | 8.4% of the class | 5%+ stakes | Source |
| May 14, 2026 | Stake report, Schedule 13G, by BANK OF AMERICA CORP /DE/ | 5.1% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by JANUS HENDERSON GROUP PLC | — | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by Northpond Ventures, LP | — | 5%+ stakes | Source |
| February 13, 2026 | Stake report, Schedule 13G/A, by Frazier Life Sciences Public Fund, L.P. | — | 5%+ stakes | Source |
| January 9, 2026 | Stake report, Schedule 13G, by EcoR1 Capital, LLC | 9.4% of the class | 5%+ stakes | Source |
| January 6, 2026 | Stake report, Schedule 13G, by 683 Capital Management, LLC | 8.18% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by JANUS HENDERSON GROUP PLC | 10.2% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by Mangrove Partners IM, LLC | 4.9% of the class | 5%+ stakes | Source |
| August 14, 2025 | Stake report, Schedule 13G/A, by Frazier Life Sciences Public Fund, L.P. | 4.1% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Mereo BioPharma Group plc now and the warning signs.
Free to see. No signup.
Keep reading
More on Mereo BioPharma Group plc and the records around it.
Mereo BioPharma Group plc elsewhere on the record
- 5%+ stake filings Oct 2026
- Who owns it
Companies that share a holder
- Mangrove Partners IM, LLC also filed stake reports on 2 other companies: ChampionsGate Acquisition Corp (Jul 2026), ClearThink 1 Acquisition Corp. (Jul 2026)
- 683 Capital Management, LLC also filed stake reports on 10 other companies: Perceptive Capital Solutions Corp (Aug 2026), Gossamer Bio, Inc. (Jun 2026), FRACTYL HEALTH, INC. (May 2026)
- EcoR1 Capital, LLC also filed stake reports on 20 other companies: Alto Neuroscience, Inc. (Jul 2026), Fulcrum Therapeutics, Inc. (Jun 2026), Eloxx Pharmaceuticals, Inc. (Jun 2026)
Watch Mereo BioPharma Group plc
Get an email when Mereo BioPharma Group plc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Mereo BioPharma Group plc?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Mereo BioPharma Group plc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Mereo BioPharma Group plc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 13 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-03-27 | Reported | not named in the filing | 8-K, 2026-03-27 |
New leaders reset buying decisions — get the Full Report on Mereo BioPharma Group plc: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the senior executive at Mereo BioPharma Group plc, with the record behind each one.
Find candidates like senior executive at Mereo BioPharma Group plcEvery change, in the filing's words
Reported
(the "Company") that she will not stand for re-election as a Director of the Board of Directors (the "Board") of the Company at the Company's 2026 annual general meeting of shareholders (the "2026 AGM"), scheduled for May 14, 2026.
- - Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
- On March 26, 2026, Dr. Annalisa Jenkins informed Mereo BioPharma plc.
- Dr. Jenkins will continue to serve out the remainder of her term, which will expire immediately prior to the 2026 AGM.
- Dr. Jenkins' decision not to stand for re-election did not result from any disagreement with the Company or the Board on any matter relating to the Company's operations, policies or practices.
Tools for this story
Each opens in a new tab, filled in for Mereo BioPharma Group plc. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.
